These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade. Van der Walt A; Butzkueven H; Kolbe S; Marriott M; Alexandrou E; Gresle M; Egan G; Kilpatrick T Pharmacol Ther; 2010 Apr; 126(1):82-93. PubMed ID: 20122960 [TBL] [Abstract][Full Text] [Related]
4. Modern multiple sclerosis treatment - what is approved, what is on the horizon. Pilz G; Wipfler P; Ladurner G; Kraus J Drug Discov Today; 2008 Dec; 13(23-24):1013-25. PubMed ID: 18775508 [TBL] [Abstract][Full Text] [Related]
5. Drug therapies for the treatment of multiple sclerosis. Ryan M J Infus Nurs; 2009; 32(3):137-44. PubMed ID: 19444021 [TBL] [Abstract][Full Text] [Related]
6. Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Hemmer B; Hartung HP Ann Neurol; 2007 Oct; 62(4):314-26. PubMed ID: 17969020 [TBL] [Abstract][Full Text] [Related]
8. [Rationale for an early treatment of multiple sclerosis]. Comi G; Martino G Rev Neurol; 2000 Jun 16-30; 30(12):1265-8. PubMed ID: 10935262 [TBL] [Abstract][Full Text] [Related]
9. Advancement of therapies for neuroprotection in multiple sclerosis. Lo A Expert Rev Neurother; 2008 Sep; 8(9):1355-66. PubMed ID: 18759548 [TBL] [Abstract][Full Text] [Related]
11. Current disease-modifying therapies in multiple sclerosis. Kieseier BC; Hartung HP Semin Neurol; 2003 Jun; 23(2):133-46. PubMed ID: 12894379 [TBL] [Abstract][Full Text] [Related]
12. Knowns and unknowns in the future of multiple sclerosis treatment. Stüve O J Neurol Sci; 2009 Dec; 287 Suppl 1():S30-6. PubMed ID: 20106346 [TBL] [Abstract][Full Text] [Related]
13. Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions. Frohman EM; Filippi M; Stuve O; Waxman SG; Corboy J; Phillips JT; Lucchinetti C; Wilken J; Karandikar N; Hemmer B; Monson N; De Keyser J; Hartung H; Steinman L; Oksenberg JR; Cree BA; Hauser S; Racke MK Arch Neurol; 2005 Sep; 62(9):1345-56. PubMed ID: 16157741 [TBL] [Abstract][Full Text] [Related]
14. Drug insight: using monoclonal antibodies to treat multiple sclerosis. Hohlfeld R; Wekerle H Nat Clin Pract Neurol; 2005 Nov; 1(1):34-44. PubMed ID: 16932490 [TBL] [Abstract][Full Text] [Related]
15. New directions in MS therapeutics: vehicles of hope. Fox RJ; Ransohoff RM Trends Immunol; 2004 Dec; 25(12):632-6. PubMed ID: 15530830 [TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of multiple sclerosis--current practice and future directions. Tullman MJ; Lublin FD; Miller AE J Rehabil Res Dev; 2002; 39(2):273-85. PubMed ID: 12051470 [TBL] [Abstract][Full Text] [Related]
18. Predicting and preventing the future: actively managing multiple sclerosis. Hutchinson M Pract Neurol; 2009 Jun; 9(3):133-43, discussion 144. PubMed ID: 19448055 [TBL] [Abstract][Full Text] [Related]
19. The impact of interferon-beta treatment on the blood-brain barrier. Kraus J; Oschmann P Drug Discov Today; 2006 Aug; 11(15-16):755-62. PubMed ID: 16846804 [TBL] [Abstract][Full Text] [Related]
20. Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options. Wipfler P; Harrer A; Pilz G; Oppermann K; Trinka E; Kraus J Drug Discov Today; 2011 Jan; 16(1-2):8-21. PubMed ID: 21055477 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]